The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.
Keywords: Cabozantinib; European Association of Urology; Guidelines; Nivolumab; Renal cancer.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.